Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 5/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

75%

3 trials in Phase 3/4

Results Transparency

100%

4 of 4 completed trials have results

Key Signals

4 with results

Enrollment Performance

Analytics

Phase 4

2(50.0%)

Phase 1

1(25.0%)

Phase 3

1(25.0%)

4Total

Phase 4(2)

Phase 1(1)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials

NCT02344290Phase 3Completed

Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults

Role: collaborator

NCT01695954Phase 1Completed

Pharmacokinetic Study of Pitavastatin and Ritonavir-Boosted Darunavir or Efavirenz

Role: collaborator

NCT01660191Phase 4Completed

A Study Comparing CoQ10 Levels While Taking 3 Different Statins

Role: collaborator

NCT01301066Phase 4Completed

A 12-Week Study Comparing Pitavastatin 4 mg vs. Pravastatin 40 mg in HIV-Infected Subjects

Role: collaborator

All 4 trials loaded